LaFleur & Godfrey LLC held its position in Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,800 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. LaFleur & Godfrey LLC’s holdings in Celgene Corporation were worth $364,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Grisanti Capital Management LLC bought a new stake in Celgene Corporation during the 2nd quarter worth approximately $3,616,000. Wedbush Securities Inc. grew its position in Celgene Corporation by 1.9% during the 2nd quarter. Wedbush Securities Inc. now owns 31,477 shares of the biopharmaceutical company’s stock worth $4,088,000 after acquiring an additional 600 shares during the last quarter. Traynor Capital Management Inc. grew its position in Celgene Corporation by 9.3% during the 2nd quarter. Traynor Capital Management Inc. now owns 14,204 shares of the biopharmaceutical company’s stock worth $1,904,000 after acquiring an additional 1,209 shares during the last quarter. Rhumbline Advisers grew its position in Celgene Corporation by 2.5% during the 2nd quarter. Rhumbline Advisers now owns 1,312,360 shares of the biopharmaceutical company’s stock worth $170,436,000 after acquiring an additional 32,357 shares during the last quarter. Finally, BTC Capital Management Inc. grew its position in Celgene Corporation by 1.3% during the 2nd quarter. BTC Capital Management Inc. now owns 33,164 shares of the biopharmaceutical company’s stock worth $4,302,000 after acquiring an additional 429 shares during the last quarter. Institutional investors and hedge funds own 79.36% of the company’s stock.

In other news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now owns 3,925 shares in the company, valued at $564,768.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ernest Mario sold 18,506 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the transaction, the director now owns 69,424 shares in the company, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. Insiders have sold 46,233 shares of company stock worth $6,268,259 in the last quarter. Company insiders own 0.95% of the company’s stock.

Celgene Corporation (NASDAQ:CELG) opened at 138.50 on Friday. The firm’s 50-day moving average price is $140.52 and its 200-day moving average price is $129.98. The company has a market cap of $108.36 billion, a PE ratio of 42.89 and a beta of 1.88. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $147.17.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the prior year, the business earned $1.44 earnings per share. The business’s quarterly revenue was up 18.7% compared to the same quarter last year. Equities research analysts forecast that Celgene Corporation will post $7.33 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “LaFleur & Godfrey LLC Continues to Hold Stake in Celgene Corporation (CELG)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/10/13/lafleur-godfrey-llc-continues-to-hold-stake-in-celgene-corporation-celg.html.

A number of research firms recently commented on CELG. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $175.00 price target (up from $148.00) on shares of Celgene Corporation in a research report on Monday, July 31st. Cantor Fitzgerald set a $160.00 price target on Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, July 27th. BMO Capital Markets restated an “outperform” rating and set a $160.00 price target (up from $152.00) on shares of Celgene Corporation in a research report on Friday, July 28th. BidaskClub upgraded Celgene Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Finally, Mizuho set a $134.00 price target on Celgene Corporation and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and twenty-two have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $150.60.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.